Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7247669 plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in first-line PD-L1-positive advanced triple-negative breast cancer
NL-OMON53202Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tobemstomig in triple-negative breast cancer (TNBC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: withdrawn.
02
Drugs
tobemstomig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON53202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53202.